Stock futures edged lower Monday morning to kick off February’s final trading week, as investors assessed President Trump’s new 15% across-the-board tariffs imposed after last week’s Supreme Court ruling against his prior emergency levies.
Here are some of Monday’s biggest stock movers:
Biggest stock gainers
- Vanda Pharmaceuticals (VNDA) +33% – Shares surged after the U.S. FDA approved Bysanti (milsaperidone) to treat bipolar I disorder and schizophrenia. The drug is an active metabolite of Fanapt (iloperidone), with studies showing bioequivalence. Bysanti is also being evaluated in a Phase 3 trial as an add-on therapy for major depressive disorder.
Biggest stock losers
- Novo Nordisk (NVO) -10% – Shares plunged after its experimental obesity drug CagriSema failed to meet a key endpoint in a head-to-head study versus Eli Lilly’s (LLY) tirzepatide, adding to competitive pressure in the weight-loss market. The setback comes as Novo faces rising competition despite the success of Wegovy and Ozempic, with the stock already down sharply in 2025.
- VF Corp. (VFC) -4% – Shares fell after JPMorgan downgraded the stock to Underweight from Neutral and cut profit forecasts. Analyst Matthew Boss lowered FY2027 EPS to $0.99 and FY2028 EPS to $1.26, both below consensus, and set an $18 price target, implying about 15% downside.